Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16892969 | 0.83 | ALDH1A1 (0.57) | ALDH1A1MAPTKDM4ETSHRL3MBTL1 | |
| SCHEMBL7204676 | 0.83 | ALDH1A1 (0.77) | ALDH1A1MAPTKDM4ETSHRL3MBTL1 | |
| SCHEMBL13997417 | 0.80 | ALDH1A1 (0.68) | ALDH1A1MAPTKDM4ETSHRL3MBTL1 | |
| SCHEMBL31588120 | 0.79 | ALDH1A1 (0.66) | ALDH1A1MAPTKDM4ETSHRL3MBTL1 | |
| SCHEMBL11179508 | 0.79 | ALDH1A1 (0.66) | ALDH1A1MAPTKDM4ETSHRL3MBTL1 | |
| SCHEMBL1143451 | 0.79 | POLB (0.72) | ALDH1A1MAPTKDM4ETSHRL3MBTL1 | |
| SCHEMBL30414489 | 0.79 | POLB (0.72) | ALDH1A1MAPTKDM4ETSHRL3MBTL1 | |
| SCHEMBL17148215 | 0.78 | SMN1; SMN2 (0.66) | ALDH1A1TSHRLMNAPOLBSMN1; SMN2 | |
| SCHEMBL4177072 | 0.77 | ALDH1A1 (0.68) | ALDH1A1MAPTKDM4ETSHRL3MBTL1 | |
| SCHEMBL8246326 | 0.77 | ALDH1A1 (0.62) | ALDH1A1MAPTKDM4EL3MBTL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158825-B2 | Modified malonate derivatives | MERCK SHARP & DOHME CORP. (US) | 2012-04-17 | — | — | US | disclosed |
| US-20100160327-A1 | Modified Malonate Derivatives | MERCK SHARP & DOHME LLC | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160327-A1 | Modified Malonate Derivatives | ME2, ME3, ME1 | ALDH1A1 784/4885MAPT 1502/4885KDM4E 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.